Director at Collegium (COLL) awarded 17,482 restricted stock units

Rhea-AI Filing Summary

Glancy Donovan Michael reported acquisition or exercise transactions in this Form 4 filing.

COLLEGIUM PHARMACEUTICAL, INC director Michael Glancy was granted 17,482 restricted stock units on May 14, 2026 at no cash cost. Two equal tranches of 8,741 RSUs are scheduled to vest around May 14, 2027, contingent on continued board service, leaving him with 17,482 shares reported following the grant.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Glancy Donovan Michael

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	17,482	$0.00	--

Holdings After Transaction: Common Stock — 17,482 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSUs granted: 17,482 RSUs Transaction price per share: $0.00 per share Shares after transaction: 17,482 shares +2 more

5 metrics

RSUs granted 17,482 RSUs Equity award to director on May 14, 2026

Transaction price per share $0.00 per share Reported price for RSU grant

Shares after transaction 17,482 shares Total shares following transaction

First vesting tranche 8,741 RSUs Vests on earlier of May 14, 2027 or 2027 annual meeting

Second vesting tranche 8,741 RSUs Vests on May 14, 2027

Key Terms

restricted stock units ("RSUs"), Annual Meeting of Shareholders, change in control, Board of Directors

4 terms

restricted stock units ("RSUs") financial

"Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

Annual Meeting of Shareholders financial

"8,741 of the RSUs vest on the earlier of May 14, 2027, or the date of the Issuer's 2027 Annual Meeting of Shareholders"

A yearly gathering where a company’s owners (shareholders) vote on key items like electing the board, approving executive pay, and ratifying auditors, and receive updates on performance and strategy. Think of it as an annual town hall for owners: it matters to investors because outcomes and disclosures can affect leadership, corporate direction, dividend and governance policies, and therefore the company’s risk and potential return.

change in control financial

"on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

Board of Directors financial

"upon the election of the director, on the earlier of the end of the director's service on the Board of Directors"

The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Glancy Donovan Michael

(Last) (First) (Middle)

C/O COLLEGIUM PHARMACEUTICAL, INC.

100 TECHNOLOGY CENTER DRIVE

(Street)

STOUGHTON MASSACHUSETTS 02072

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
COLLEGIUM PHARMACEUTICAL, INC [ COLL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/14/2026		A(1)		17,482	A	$0	17,482	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. 8,741 of the RSUs vest on the earlier of May 14, 2027, or the date of the Issuer's 2027 Annual Meeting of Shareholders; 8,741 of the RSUs vest on May 14, 2027, in each case subject to the director's continued service with the Issuer. The RSUs will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer, in shares of the Issuer's common stock.

	/s/ Colleen Tupper as Attorney-In-Fact For Michael Donovan	05/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did COLL director Michael Glancy report?

Director Michael Glancy reported receiving a grant of 17,482 restricted stock units. These RSUs represent a contingent right to receive an equal number of Collegium Pharmaceutical common shares, subject to vesting conditions tied to future board service and specified dates.

How many COLLEGIUM PHARMACEUTICAL (COLL) RSUs were granted in this Form 4?

The Form 4 shows a grant of 17,482 restricted stock units. Each RSU corresponds to one share of Collegium Pharmaceutical common stock, giving the director potential future ownership of 17,482 shares if all vesting and service conditions are satisfied.

What is the vesting schedule for Michael Glancy’s 17,482 COLL RSUs?

The 17,482 RSUs vest in two equal tranches of 8,741 units. One tranche vests on the earlier of May 14, 2027 or the 2027 annual shareholder meeting, and the second tranche vests on May 14, 2027, all subject to continued board service.

Did Michael Glancy pay a purchase price for the COLL RSU grant?

The reported transaction price per share is $0.00, indicating no cash purchase price for the 17,482 RSUs. This reflects a compensation-related equity award rather than an open-market stock purchase by the director in this Form 4 filing.

When will the granted COLL RSUs be settled into common stock?

The RSUs will be settled in common shares upon vesting or, if the director elects, at the earlier of board service end, death, disability, or a change in control. Settlement depends on these specified events and the applicable vesting conditions.

How many COLL shares does Michael Glancy report owning after this RSU grant?

After the reported transaction, the Form 4 lists total shares following the transaction of 17,482. This figure reflects the equity position reported in connection with the RSU award and provides the post-grant holding disclosed in this filing.